We observed that amplification of EIF4G1 were prominent in prostate cancer (~ 25%), ovarian cancer (~ 15%), Head and neck cancer (~ 13%) and cervical cancer (~ 12.5%). Here, EIF4G1 is linked to head and neck cancer.